Gómez-Martínez Sofia, Brufau-Cochs Magí, de la Iglesia-Martín Javier, Amat-Samaranch Victoria, Aguilera-Peiró Paula
Department of Dermatology, Hospital Clínic de Barcelona, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
Contact Dermatitis. 2025 Apr;92(4):277-282. doi: 10.1111/cod.14743. Epub 2024 Dec 23.
The European Photopatch Testing Baseline Series (EPTBS) was published in 2013. However, limited data exist regarding the real-world clinical application of the EPTBS.
This study aims to describe the photopatch test experience with the EPTBS over 11 years at a tertiary hospital in Spain.
A retrospective chart review spanning from February 2012 to October 2023 was conducted on patients who underwent photopatch testing (PPT) with the EPTBS. Additionally, patch testing was performed on all patients according to the European recommendations.
Data from 148 patients were collected, and showed a PPT positivity rate of 7.4% (n = 11). Specifically, we found a photoallergic contact dermatitis (PACD) in 11/148 patients (15 positive reactions to 8 different allergens, including one patient own's product). Of them, 87% had current relevance and non-steroidal anti-inflammatory drugs (NSAIDS) were the main culprits of PACD (60%). Alternatively, we found a contact allergy to the EPTBS allergens in 14/148 (9.3%) patients, (21 positive reactions both in the irradiated and non-irradiated set to 17 different allergens, including many patients' products). Of them, UV solar filters represented the main cause of ACD. Regarding the patch testing results, we observed a positivity rate of 39.9% (116 positives in 59 different patients). The most frequent were methylchloroisothiazolinone/methylisothiazolinone, fragrance mix I and II and Myroxylon pereirae resin (balsam of Peru).
EPTBS implementation has permitted a more accurate study of PACD. Our positivity rate for PPT is slightly lower than previous reports, however the main culprits for PACD remain to be NSAIDS. The inclusion of contact allergens applied in photoexposed areas in the EPTBS could contribute to discriminating between PACD, photoaggravated ACD and ACD.
欧洲光斑贴试验基线系列（EPTBS）于2013年发布。然而，关于EPTBS在实际临床应用中的数据有限。
本研究旨在描述西班牙一家三级医院11年来使用EPTBS进行光斑贴试验的经验。
对2012年2月至2023年10月期间接受EPTBS光斑贴试验（PPT）的患者进行回顾性病历审查。此外，根据欧洲建议对所有患者进行斑贴试验。
收集了148例患者的数据，PPT阳性率为7.4%（n = 11）。具体而言，我们在11/148例患者中发现了光变应性接触性皮炎（PACD）（对8种不同变应原出现15次阳性反应，其中包括1例患者自身的产品）。其中，87%具有当前相关性，非甾体抗炎药（NSAIDS）是PACD的主要病因（60%）。另外，我们在14/148（9.3%）例患者中发现对EPTBS变应原的接触性过敏（在照射组和未照射组中对17种不同变应原出现21次阳性反应，其中包括许多患者的产品）。其中，紫外线防晒剂是ACD的主要原因。关于斑贴试验结果，我们观察到阳性率为39.9%（59例不同患者中有116例阳性）。最常见的是甲基氯异噻唑啉酮/甲基异噻唑啉酮、香料混合物I和II以及秘鲁香脂（秘鲁胶）。
EPTBS的实施使对PACD的研究更加准确。我们的PPT阳性率略低于先前报告，但PACD的主要病因仍然是NSAIDS。在EPTBS中纳入暴露于光的区域所应用的接触性变应原，可能有助于区分PACD、光加重性ACD和ACD。
